PHENAZINE-35 Drug Patent Profile

« Back to Dashboard

Which patents cover Phenazine-35, and when can generic versions of Phenazine-35 launch?

Phenazine-35 is a drug marketed by Abc Holding and is included in one NDA.

The generic ingredient in PHENAZINE-35 is phendimetrazine tartrate. Twelve suppliers are listed for this compound. Additional details are available on the phendimetrazine tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Phenazine-35

A generic version of PHENAZINE-35 was approved as phendimetrazine tartrate by CHARTWELL on October 30^th, 1991.

Summary for PHENAZINE-35

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for PHENAZINE-35

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abc Holding	PHENAZINE-35	phendimetrazine tartrate	TABLET;ORAL	085512-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Last updated: February 3, 2026

What Is the Current Investment Landscape for PHENAZINE-35?

PHENAZINE-35, a phenothiazine derivative, is primarily used for the treatment of schizophrenia and other psychotic disorders. Its market presence is limited, with some off-label uses. Investment potential hinges on regulatory status, patent protection, and clinical development pathways. Currently, PHENAZINE-35 faces limited patent exclusivity, with generics available in many regions, constraining pricing power and profit margins.

What Are the Fundamental Attributes of PHENAZINE-35?

Regulatory Status

• Approval: Widely approved in Europe, Asia, and parts of Latin America since the 1950s.
• Patents: No recent patents filed, with patents expired in most territories.
• Regulation: Classified as a generic drug in multiple jurisdictions, facing typical regulatory challenges for new approvals.

Market Dynamics

• Size: Estimated global market for antipsychotics was approximately $15 billion in 2021, with phenothiazines representing less than 5% due to obsolescence.
• Competitors: Second-generation antipsychotics such as risperidone, olanzapine, and quetiapine dominate, rendering PHENAZINE-35 a niche or off-label product.
• Pricing: Generic versions sell at margins close to production costs in mature markets.

Clinical Development and Safety Profile

• Efficacy: Proven efficacy in schizophrenia but with significant side effects such as extrapyramidal symptoms and sedation.
• Safety: Risk of tardive dyskinesia limits widespread use, especially in a landscape favoring drugs with improved side effect profiles.
• Research: Limited ongoing clinical research or trials for new indications.

Manufacturing and Supply Chain

• Production: Established manufacturing processes are simple but face price erosion due to competition.
• Supply Chain: Well-established, with multiple facilities globally.

Financial and Investment Considerations

Aspect	Details
Revenue Potential	Low to moderate, constrained by generics and competition
Margins	Compressed by generic competition
Investment Risk	High; substantial regulatory, market, and patent risks
Entry Barriers	Low; easy entry for competitors
R&D Cost	Minimal, limited ongoing development

How Does PHENAZINE-35 Hold Up Compared to Competitors?

Drug	Category	Advantage	Disadvantage
PHENAZINE-35	First-generation antipsychotic	Established efficacy, low R&D needs	Side effects, patent expired, market decline
Risperidone	Second-generation antipsychotic	Better side effect profile	Higher cost, patent expiration approaching
Clozapine	Second-generation antipsychotic	Effective for treatment-resistant cases	Risk of agranulocytosis, monitoring requirements

What Is the Outlook for Future Investment?

• Regulatory landscape: Not favorable due to existing generics and limited new data.
• Market trend: Shift toward newer antipsychotics with improved safety.
• Development costs: Minimal, as the drug is well-established.
• Profitability: Limited unless targeted at niche or off-label markets with differentiated formulations.

What Are the Key Risks for Investors?

• Patent expiration and generic competition.
• Regulatory restrictions related to safety concerns.
• Market shift toward newer drugs with improved side effects.
• Limited pipeline for new indications or formulations.

What Strategic Opportunities Exist?

• Developing combination therapies or formulations that reduce side effects.
• Targeting niche markets or regional markets where generic competition is less intense.
• Exploring new indications such as behavioral disturbances in neurodegenerative diseases.

Key Takeaways

• PHENAZINE-35 is an old, off-patent drug with limited growth prospects in mature markets.
• The competitive landscape favors second-generation antipsychotics with better safety profiles.
• Investment yields are constrained by low profit margins and high regulatory risks.
• Development costs are minimal, but market growth prospects are declining.
• Opportunities may exist in niche markets or repurposing for new indications.

FAQs

1. Can PHENAZINE-35 be repositioned for new medical indications?

   • Limited evidence supports new indications; strategic repositioning faces regulatory and clinical hurdles.

2. What regions offer the best investment opportunities for PHENAZINE-35?

   • Emerging markets with less generic penetration offer potential, but regulatory environments remain challenging.

3. Are there any ongoing clinical trials for PHENAZINE-35?

   • No significant current trials are identified; focus remains on established use.

4. How does side effect profile influence market longevity?

   • Significant side effects limit long-term use, especially with newer agents available.

5. What alternative investment strategies exist for antipsychotics?

   • Investing in pipeline drugs of second-generation antipsychotics or combination therapies with improved safety profiles.

---

References

1. Market data: IQVIA, "Global Trends in Antipsychotic Drug Market," 2021.
2. Regulatory overview: EMA, "Guidelines for Antipsychotic Drugs," 2022.
3. Clinical safety profile: FDA, "Phenothiazine Side Effects," 2020.
4. Competitive landscape: EvaluatePharma, "Antipsychotic Market Analysis," 2022.
5. Patent information: USPTO, "Expired Patents on Phenothiazine Derivatives," 2021.